A coalition of 45 states and territories has reached settlements with Ascend Laboratories, Citron Pharma, and Mayne Pharma to resolve allegations the generic drug manufacturers engaged in a long-running conspiracy to artificially inflate and manipulate prices and reduce competition.
Ascend will pay $400,000 to the states, while Mayne will pay $650,000. Citron’s settlement only includes non-monetary terms as it’s no longer in business. As part of the settlement, the companies each agreed to change their practices to ensure fair competition and compliance with antitrust laws.
“These companies illegally colluded to raise generic drug prices and pad their profits at consumers’ expense,” New York Attorney General Letitia James said in a statement.
Starting in 2016, the coalition of nearly all states and territories, led by Connecticut, has filed series of antitrust cases against generic drug manufacturers. The states previously reached settlements with Sandoz, Fougera, Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure, totaling $496.5 million.
“As a result of our efforts to hold generic drug manufacturers accountable for illegally conspiring to drive up prices, consumers may now be eligible to receive compensation,” California Attorney General Rob Bonta said in a statement. “I encourage anyone who purchased an eligible medication to take a few minutes to check their eligibility and submit a claim to recover money they may be owed.”
Consumers who purchased a generic prescription drug between May 2009 and December 2019 may be eligible for compensation. To determine eligibility, call 866-290-0182, email info@AGGenericDrugs.com, or visit www.AGGenericDrugs.com. Consumers can submit a claim for compensation here.
Washington and Idaho are the only states in the coalition to also secure restitution for businesses impacted by the price fixing. For more information, visit https://www.aggenericdrugs.com/English/CorporateEntities.
